Thrombolytic Retreatment for Coronary Arterial Reocclusion
Author:
Becker Richard C.
Reference98 articles.
1. Verstraete M, Bernard R, Bory M, et al: Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985;i:842–847.
2. Topol EJ, Morris DC, Smalling RW, et al: A multicenter-randomized, placebocontrolled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol 1987;9:1205–13.
3. Simoons ML, Arnold AER, Betrieu A, et al: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; i: 197–202.
4. Bates ER, Califf RM, Stack RS, et al: Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) Trial: Influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol 1989;13:12–18.
5. Cheesebro JH, Knatternd G, Roberts R, et al: Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142–154.